CCM Bio­sciences breaks out of stealth with $25M; Two biotechs merge, to fo­cus on Parkin­son's

CCM Bio­sciences launched out of stealth Tues­day, tout­ing ten drug pro­grams and more than $25 mil­lion raised from Se­ries A1 and A2 rounds.

CCM has a part­ner­ship with PMC Group, which is han­dling chem­istry, man­u­fac­tur­ing and con­trols for the biotech’s pro­grams. CCM CEO and co-founder Raj Chakrabar­ti is al­so the pres­i­dent of PMC Group In­ter­na­tion­al, ac­cord­ing to a me­dia re­lease.

A com­pa­ny pre­sen­ta­tion this month de­tailed some of CCM Bio­sciences’ drug pro­grams, in­clud­ing tar­get­ing non­sense mu­ta­tions, EGFR and KRAS for cys­tic fi­bro­sis, drug-re­sis­tant non-small cell lung can­cer and pan­cre­at­ic can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER